For example, OTUB1 has emerged as a hotspot for small-molecule inhibitor design through its Asn45/Arg86 hydrogen-bond network (205), while the OTUD3 inhibitor OTUDin3 significantly suppresses NSCLC progression by targeting the S1 ubiquitin-binding site (206). Here, OTUD3 is linked to non-small cell lung carcinoma.